Equillium to present at the h.c. wainwright autoimmune & inflammatory disease conference and the ld micro invitational conference

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the h.c. wainwright autoimmune & inflammatory disease virtual conference, and the ld micro invitational conference. management will provide an overview of the company's clinical programs, partnership with ono pharmaceutical and 2024 milestones, during bot.
EQ Ratings Summary
EQ Quant Ranking